D.Phil in Paediatrics
The Department of Paediatrics offers a variety of doctoral opportunities across its research themes. Take a look at the outlines of prospective DPhil projects - and please get in touch with the relevant supervisor to discuss the details before submitting an application. Prospective students may apply to this programme with their own research proposal. Please make sure you contact your preferred supervisor for a discussion of your project before submitting your application.
About this course
The Department has major interests in developmental immunology, infectious diseases of infancy and childhood, HIV infection and immune control, design, development and testing of vaccines, and in paediatric molecular genetics. Subject areas cover a large spectrum of paediatric medical, and scientific research.
OPEN FIELD-APPLICATIONS RECEIVED AFTER THE DECEMBER 2021 DEADLINE
There is an open field period for applications received after December 2021 for entry in October 2022 and such applications will not be considered for the departmental studentships. Please contact individual supervisors to discuss your application and research proposal before submitting an application. Such applicants will need to have independently secured awards or private funding.
Applicants in the open field need to apply for the programme via the main University graduate application form.
Course code (RD_PE1)
Graduate studies contact: firstname.lastname@example.org
To access the application form and application guide, please go to:
CLINICAL DPHIL AT OXFORD
A doctorate is an important step in any clinical academic career. At any one time, numerous doctors are undertaking a DPhil at Oxford.
For Oxford PGT students wishing to undertake a D.Phil in Paediatrics.
YOUR CONTRACT WITH THE UNIVERSITY
Please read the following information on the main University pages carefully before accepting an offer from us.
Available D.Phil projects for 2023
THE IMPACT OF APNOEA ON BRAIN ACTIVITY IN PRETERM INFANTS
Supervisor: Dr Caroline Hartley
Project outline: Apnoea - the cessation of breathing - is a common pathology associated with prematurity. These potentially life-threatening events can result in reduced cerebral oxygenation and frequent apnoeas have been associated with long-term effects including reduced childhood cognitive ability. Brain activity drives brain development during the critical preterm period but the immediate impact of apnoeas on brain activity is not well understood. The aim of this project will be to characterise the relationship between apnoeas and brain activity in preterm infants, and how this changes with development. EEG (electroencephalography) and physiology will be recorded simultaneously, and signal processing approaches will be used and developed to fully characterise this relationship. This research will enhance our understanding of apnoeas, and ultimately seeks to improve outcomes for prematurely-born children.
Contact details: email@example.com
Applications by: 8th January 2022
Further information: The focus of the lab is to understand the impact of physiological instability on brain development in premature infants. 1 in every 10 babies are born prematurely; understanding and mitigating the long-term impact of premature birth is important to improve the lives of these children. We develop novel methodologies with the aim to provide a greater understanding of infant brain development and derive tools which can be translated to the clinical setting.
Discovering muscle-specific drugs employing human iPSC-derived 3D tissue-engineered muscles.
Neuromuscular diseases comprise a diverse group of mainly inherited conditions that typically affect striated muscles including the heart, resulting in progressive degeneration of these tissues and leading to very significant morbidity and mortality. These diseases are exemplified by Duchenne muscular dystrophy (DMD) which is a fatal inherited muscle disorder that arises due to defects in the dystrophin gene abolishing production of the dystrophin protein crucial for normal muscle and heart function.
Antisense oligonucleotides (ASOs) represent one of the fastest growing genetic based drug therapies for rare diseases. The major obstacle for developing ASO-based therapeutics is intracellular delivery of these drugs to skeletal muscle and heart to correct dystrophin gene. We are focusing on developing a targeted technology utilising cell-penetrating peptide (CPP) to deliver ASOs. However, CPPs have several drawbacks including low stability and tissue specificity. We will design chimeric CPPs exploiting computational biochemistry and bioinformatics approaches to improve the peptide stability, tissue specificity and endosomal release of ASOs. We will select novel CPPs possessing the potential to enhanced internalization based on utilisation of 3D artificial human skeletal muscle and heart, recapitulating the patient-specific features of the tissue structure in collaboration with Prof Saverio Tedesco, University College of London, London, UK). The platform technology and tissue-specific motifs can be highly relevant to other myopathies, neuromuscular disorders and inherited cardiomyopathies. Our lead CPPs will be repurposed via conjugation to alternative ASOs or different therapeutic cargoes to address wider applications e.g. targeting FOXO3 transcription factor in various pathological conditions including cardiovascular disease and cancer, which is also a part of this DPhil. Furthermore, proteolysis targeting chimeric (PROTAC) technology, a new class of drugs, will be applied to mediate selective ubiquitination and degradation of FOXO3. This work will involve a range of methodological techniques including but not limited to subcellular protein fractionation, phage display biopanning, atomic force microscopy, multi-omics analysis, computational biochemistry, high-resolution fluorescence microscopy.
The Wood lab is a multidisciplinary centre of excellence within the Department, MDUK Oxford Neuromuscular Centre and Oxford Harrington Rare Disease Centre, providing a superb environment for interdisciplinary molecular and cellular science. The laboratory has many collaborations with industry including with two recent spin-out companies. The Wood group possesses a whole spectrum of resources required for the project to be successful and is housed in a new regenerative medicine institute in Oxford, the Institute of Developmental and Regenerative Medicine (IDRM) (ox.ac.uk), with access to state of the art capabilities for drug development.
Contact details: firstname.lastname@example.org
Example D.Phil Projects
EXPLORING THE EARLY RESPONSE TO (PARA)TYPHOID EXPOSURE IN A HUMAN CHALLENGE MODEL OF INFECTION
Student name: Amber Barton
Description: Several plasma cytokines have been found to transiently increase around 12 hours after healthy volunteers are experimentally exposed to Salmonella Typhi, regardless of whether they go on to develop signs of infection. This raises a number of questions, including the identity and location of the cells producing these cytokines, whether we can detect other immunological signatures of exposure, and whether such signatures differ between those who become infected and those who remain well. In this project these questions are being addressed using whole blood transcriptional analysis. Early differences in the transcriptome between individuals who remain well and those who develop disease have indicated genes which might be involved in protection. Furthermore, gene set enrichment analysis of blood transcriptional changes occurring 12 h post-exposure has allowed characterisation of early cellular responses, the significance of which is being investigated further with in vitro experiments.
Source of funding: St Cross Paediatrics Scholarship (Department of Paediatrics and St Cross College), with project support from Wellcome Trust and the Bill and Melinda Gates Foundation.
RAPAED-TB: EVALUATION OF NEW DIAGNOSTICS IN CHILDHOOD TB
Student name: Laura Olbrich
Description: Globally, children account for an estimated one million TB cases and more then 200,000 deaths due to TB per year. The main challenge is adequate and timely diagnosis as currently available diagnostic tests fail to diagnose the majority of children with TB. New testing strategies are therefore urgently needed. In a prospective, multi-country clinical study in four African countries and in India, diagnostic performance data on a number of promising novel assays and sampling strategies will be generated. In addition, the study will derive diagnostic and screening algorithms for TB using existing and these novel tests.
Source of funding: EDCTP
EVALUATING THE EFFECT OF IMMUNISATION WITH CAPSULAR GROUP B MENINGOCOCCAL VACCINES ON MENINGOCOCCAL CARRIAGE
Student name: Jeremy Carr
Description: Capsular group B meningococcal (MenB) vaccines provide direct protection against invasive MenB disease, however the effect on herd protection is not known. This study will evaluate the influence of MenB immunisation on oropharyngeal carriage in teenagers, and consequently the potential for these vaccines to disrupt transmission and provide broad community protection against MenB disease. Given the potential for immunisation with the subcapsular protein antigens in MenB vaccines to impact on the carriage of non-MenB pathogenic and commensal Neisseria species, carriage rates of these organisms will also be evaluated. Understanding the influence of MenB protein-based vaccines on herd protection will inform current vaccine policy and future vaccine development.
Source of funding: University of Oxford; Clarendon Scholarship; National Institute for Health Research; Department of Health.
ASSESSING THE IMMUNE MECHANISMS UNDERLYING THE IMMUNOGENICITY TO MENINGOCOCCAL GROUP B VACCINES
Student name: Dylan Sheerin
Description: The Gram-negative bacterium Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD), a severe bacterial infection which occurs predominantly in infants within the first years of life. Two meningococcus group B (MenB) vaccines have been licensed, but both have significant drawbacks. A novel MenB vaccine has been developed at the Oxford Vaccine Group, based on a viral vector. The vaccine candidate induced strong and persistent protective immune responses in mice after a single dose, and a phase I trial to assess its safety and immunogenicity in healthy adults is ongoing. The D.Phil student is working on understanding the mechanisms which underlie the responses induced by these distinct vaccines at the genetic, cellular and systems level, and the results will contribute to the rational design of future vaccine candidates for MenB and other bacterial diseases.
Source of funding: Medical Research Council
Further information: Currently in second year.